Thierry Lesimple
Overview
Explore the profile of Thierry Lesimple including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Louveau B, Resche-Rigon M, Lesimple T, Meda L, Pracht M, Baroudjian B, et al.
Clin Cancer Res
. 2021 May;
27(14):3876-3883.
PMID: 33947696
Purpose: In metastatic melanoma, cyclin D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I-II study,...
22.
Frelau A, Jali E, Campillo-Gimenez B, Pracht M, Porneuf M, Dinulescu M, et al.
Melanoma Res
. 2021 Apr;
31(3):208-217.
PMID: 33904517
This study aimed to assess the prognostic value of thyroid dysfunctions in metastatic melanoma patients on anti-programmed death-1 (anti-PD-1). A total of 110 stage IV or inoperable stage III melanoma...
23.
Tesileanu C, Vallentgoed W, Sanson M, Taal W, Clement P, Wick W, et al.
Acta Neuropathol
. 2021 Mar;
141(6):945-957.
PMID: 33740099
Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that...
24.
Joste M, Dion L, Brousse S, Nyangoh Timoh K, Rousseau C, Reilhac A, et al.
J Gynecol Obstet Hum Reprod
. 2021 Feb;
50(5):102091.
PMID: 33592345
Introduction: Mucosal melanomas (MM) of the female genital tract are rare a. We aimed to study the prognostic factors of vulvar and vaginal locations of MM. Material And Method: A...
25.
Lebbe C, Italiano A, Houede N, Awada A, Aftimos P, Lesimple T, et al.
Target Oncol
. 2020 Nov;
16(1):47-57.
PMID: 33211315
Background: Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. Objectives: The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at...
26.
Delord J, Italiano A, Awada A, Aftimos P, Houede N, Lebbe C, et al.
Target Oncol
. 2020 Nov;
16(1):37-46.
PMID: 33170484
Background: The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-competitive MEK1/2 inhibitor. Objective:...
27.
Bhave P, Pallan L, Long G, Menzies A, Atkinson V, Cohen J, et al.
Br J Cancer
. 2020 Oct;
124(3):574-580.
PMID: 33087895
Background: Adjuvant targeted therapy (TT) improves relapse free survival in patients with resected BRAF mutant stage III melanoma. The outcomes and optimal management of patients who relapse after adjuvant TT...
28.
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017
Poizeau F, Kerbrat S, Happe A, Rault C, Drezen E, Balusson F, et al.
J Invest Dermatol
. 2020 Oct;
141(4):830-839.e3.
PMID: 33049268
Immune checkpoint inhibitors and targeted therapies have profoundly altered the management of several cancers over the past decade. Metastatic melanoma has been at the forefront of these changes. We provide...
29.
Frelau A, Palard-Novello X, Jali E, Boussemart L, Dupuy A, James P, et al.
Cancer Immunol Immunother
. 2020 Sep;
70(3):679-687.
PMID: 32880684
Purpose: To determine performances of 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography (PET) to detect the development of permanent thyroid dysfunction (PTD), and to evaluate the prognostic value of early increased thyroid...
30.
Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood J, et al.
N Engl J Med
. 2020 Sep;
383(12):1139-1148.
PMID: 32877599
Background: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with...